click for access


Ashktorab H, Rahi H, Nouraie M, Shokrani B, Lee E, Haydari T, Laiyemo AO, Siegel P, Brim H. (2018). GPNMB methylation: a new marker of potentially carcinogenic colon lesions.BMC Cancer. 2018 Nov 6.

Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehuédé C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. (2018). Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.Cell Metab. 2018 Sep 17.

Andrzejewski S, Siegel PM, St-Pierre J. (2018). Metabolic Profiles Associated With Metformin Efficacy in Cancer.Front Endocrinol (Lausanne). 2018 Aug 21.

Poffenberger MC, Metcalfe-Roach A, Aguilar E, Chen J, Hsu BE, Wong AH, Johnson RM, Flynn B, Samborska B, Ma EH, Gravel SP, Tonelli L, Devorkin L, Kim P, Hall A, Izreig S, Loginicheva E, Beauchemin N, Siegel PM, Artyomov MN, Lum JJ, Zogopoulos G, Blagih J, Jones RG. (2018). LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. Science. 2018 Jul 27.

Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN. (2018). Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clin Cancer Res. 2018 Jun 14.

Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, Park M, Siegel PM, Shore GC, Roulston A. (2018). DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anticancer Drugs. 2018 Sep;29.

Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A. (2018). EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene. 2018 Jul.

Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. (2018). Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018 Jun.

Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, Miller WH Jr., Ramón Y Cajal S, Park M, Jones RG, Piccirillo CA, Siegel PM, Sonenberg N. (2018). Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. Proc Natl Acad Sci U S A. 2018 Feb 20.

Annis MG, Ouellet V, Rennhack JP, L'Esperance S, Rancourt C, Mes-Masson AM, Andrechek ER, Siegel PM. (2018) .Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.Breast Cancer Res. 2018 Jan 30.



Ngan E, Kiepas A, Brown CM, Siegel PM. (2017). Emerging roles for LPP in metastatic cancer progression. J Cell Commun Signal. 2017 Oct 13.

Andrzejewski S, Klimcakova E, Johnson RM, Tabariès S, Annis MG, McGuirk S, Northey JJ, Chénard V, Sriram U, Papadopoli DJ, Siegel PM, St-Pierre J. (2017). PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.Cell Metab. 2017 Nov 7.

Rose AAN, Biondini M, Curiel R, Siegel PM.(2017). Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.Pharmacol Ther. 2017 Nov.

Ngan E, Stoletov K, Smith HW, Common J, Muller WJ, Lewis JD, Siegel PM. (2017). LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis.Nat Commun. 2017 Apr 24.

Hsu BE, Siegel PM. (2017). Expanding the armamentarium for neutrophil-mediated angiogenesis. Hepatology. 2017 Jun.

He Y, Northey JJ, Pelletier A, Kos Z, Meunier L, Haibe-Kains B, Mes-Masson AM, Côté JF, Siegel PM, Lamarche-Vane N.(2017). The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer. Oncogene. 2017 Jun.

Tabariès S, Siegel PM. (2017). Role of Claudins in Cancer Metastasis. Oncogene. 2017 Mar.

Nooh A, Zhang YL, Sato D, Rosenzweig DH, Tabariès S, Siegel P, Barralet JE, Weber MH. (2017). Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. J Bone Oncol. 2017 Jan 13.



Wieczorek M, Tcherkezian J, Bernier C, Prota AE, Chaaban S, Rolland Y, Godbout C, Hancock MA, Arezzo JC, Ocal O, Rocha C, Olieric N, Hall A, Ding H, Bramoullé A, Annis MG, Zogopoulos G, Harran PG, Wilkie TM, Brekken RA, Siegel PM, Steinmetz MO, Shore GC, Brouhard GJ, Roulston A. (2016). The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med. 2016 Nov 16.

Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. (2016). MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res. 2016 Dec 15.

Rajadurai CV, Havrylov S, Coelho PP, Ratcliffe CD, Zaoui K, Huang BH, Monast A, Chughtai N, Sangwan V, Gertler FB, Siegel PM, Park M. (2016). 5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. J Cell Biol. 2016 Sep 12.

Lehuédé C, Dupuy F, Rabinovitch R, Jones RG, Siegel PM. (2016). Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. Cancer Res. 2016 Sep 15.

Pedanou VE, Gobeil S, Tabariès S, Simone TM, Zhu LJ, Siegel PM, Green MR. (2016). The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. Elife. 2016 Jul 29.

Ha JR, Siegel PM, Ursini-Siegel J.(2016). The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. J Cell Biochem. 2016 Sep.

Fernandes R, Siegel P, Komarova S, Hilton J, Addison C, Ibrahim MF, Werier J, Dennis K, Singh G, Amir E, Jarvis V, Emmenegger U, Mazzarello S, Clemons M. (2016). Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS). J Bone Oncol. 2016 Feb 23.

Singh SR, Rameshwar P, Siegel P.(2016).Targeting tumor microenvironment in cancer therapy.Cancer Lett. 2016 Sep 28.

Cyr-Depauw C, Northey JJ, Tabariès S, Annis MG, Dong Z, Cory S, Hallett M, Rennhack JP, Andrechek ER, Siegel PM.(2016).Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion. Mol Cell Biol. 2016 May 2.


Ursini-Siegel J, Siegel PM. (2015). The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett. 2015 Nov 11.

Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, Negi S, Awan Z, Aikin R, Kwan J, Amre R, Tabaries S, Hassanain M, Seidah NG, Maluccio M, Siegel P, Metrakos P. (2015). Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015 Dec 16.

Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM. (2015). PDK1-Dependent metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell metab. 2015 Sep 9.

Rafiei S, Tiedemann K, Tabariès S, Siegel PM, Komarova SV. (2015). Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.Cancer Lett. 2015 Jun 1;361(2):262-70.

Tabariès S, Annis MG, Hsu BE, Tam CE, Savage P, Park M, Siegel PM. (2015).Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.Oncotarget. 2015 Apr 20;6(11):9476-87.

Wang N, Rayes RF, Elahi SM, Lu Y, Hancock MA, Massie B, Rowe GE, Aomari H, Hossain S, Durocher Y, Pinard M, Tabariès S, Siegel PM, Brodt P.(2015). The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis.Mol Cancer Ther. 2015 Apr;14(4):982-93.

Li H, Bergeron S, Annis MG, Siegel PM, Juncker D. (2015).Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray.Mol Cell Proteomics. 2015 Apr;14(4):1024-37.

Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, Carmona E, Tam CE, Mes-Masson AM, Siegel PM.(2015). Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res. 2015 Mar;27;17:45

Maric G, Annis MG, Dong Z, Rose AA, Ng S, Perkins D, MacDonald PA, Ouellet V, Russo C, Siegel PM. (2015).GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.Oncogene. 2015 Mar 16.

Pettersson F, Del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Siegel PM, Miller WH Jr. (2015). Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.Cancer Res. 2015 Mar 15;75(6):1102-12.



Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L. (2014). Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.J Clin Oncol. 2014 Nov 10;32(32):3619-25.

Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, Browd S, Geyer JR, Leary S, Jallo G, Cohen K, Gupta N, Prados MD, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Malkin H, Ligon AH, Albrecht S, Pfister SM, Ligon KL, Majewski J, Jabado N, Kieran MW.(2014). Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May;46(5):462-6

Guilbert C, Annis MG, Dong Z, Siegel PM, Miller WH Jr, Mann KK.(2014). Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer. PLoS One. 2013 Dec 31;8(12):e85995.

Kleinman CL, Gerges N, Papillon-Cavanagh S, Sin-Chan P, Pramatarova A, Quang DA, Adoue V, Busche S, Caron M, Djambazian H, Bemmo A, Fontebasso AM, Spence T, Schwartzentruber J, Albrecht S, Hauser P, Garami M, Klekner A, Bognar L, Montes JL, Staffa A, Montpetit A, Berube P, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel PM, Duchaine T, Perotti C, Fleming A, Faury D, Remke M, Gallo M, Dirks P, Taylor MD, Sladek R, Pastinen T, Chan JA, Huang A, Majewski J, Jabado N.(2014). Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014 Jan;46(1):39-44


Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C, Dong Z, Siwak DR, Annis MG, Mills GB, Muller WJ, Siegel PM, Jones RG.(2013). LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer Metab. 2013 Aug 14;1(1):18

Maric G, Rose AA, Annis MG, Siegel PM.(2013). Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther. 2013 Jul 9;6:839-52

Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, Park M, Hallett M, Siegel PM, Pawson T, Ursini-Siegel J.(2013). The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression. Cancer Res. 2013 Jul 15;73(14):4521-32

Ngan E, Northey JJ, Brown CM, Ursini-Siegel J, Siegel PM.(2013). A complex containing LPP and α-Actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells. J Cell Sci. 2013 May 1;126(Pt 9):1981-91

Northey JJ, Dong Z, Ngan E, Kaplan A, Hardy WR, Pawson T, Siegel PM.(2013). Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasis. J Biol Chem. 2013 Feb 15;288(7):5210-22

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG.(2013). AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013 Jan 8;17(1):113-24


Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM.(2012). ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res. 2012 Nov 22;14(6):R149

Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM.(2012). Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes.Mol Cell Biol. 2012 Aug;32(15):2979-91

Ouellet V, Siegel PM. (2012). CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. J Cell Commun Signal. 2012 June;6(2):73-85

Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallet M, Siegel P, Park M. (2012). Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res. 2012 May 8;14(3):R74

Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.. Nature. 2012 Jan 29;482(7384):226-31

Tabaries S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. (2012). Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol.

Ouellet V, Siegel PM.(2012). CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis.. J Cell Commun Signal Jun;6(2):73-85.


Li J, Karaplis AC, Huang DC, Siegel PM, Camirand A, Yang XF, Muller WJ, Kremer R. (2011). PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy targets. J Clin Invest. Dec 1;121(12):4655-69.

Labelle-Côté M, Dusseault J, Ismaïl S, Picard-Cloutier A, Siegel PM, Larose L.(2011). Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivo. BMC Cancer. Oct 12;11:443.

Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel PM. (2011). CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol. 2011 May;178(5):2377-88.

S. Tabariès, Z. Dong, M.G. Annis, A. Omeroglu, F. Pepin, V. Ouellet, C. Russo, M. Hassanain, P. Metrakos, Z. Diaz, M. Basik, N. Bertos, M. Park, C. Guettier, R. Adam, M. Hallett and P.M. Siegel (2011). Claudin-2 enhances integrin-mediated breast cancer cell adhesion and promotes liver metastasis. Oncogene 30, 1318-1328.

Y.He, J.J. Northey, M. Primeau, R.D. Machado, R. Trembath, P.M. Siegel and N. Lamarche-Vane (2011). CdGAP is required for Transforming Growth Factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Oncogene 30, 1032-1045

S. Hassan, M. Buchanan, L. Gaboury, W. Muller, A. Alsawafi, A. Mourskaia, P. Siegel and M. Basik. (2011). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J Cancer, 129:1, 225–232.


A. Bemmo, C. Dias, A.A.N. Rose, C. Russo, P. Siegel and J. Majewski. (2010). Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities. PLoS One 5(8). pii: e11981.

M. Demers, A.A.N. Rose, A.A. Grosset, L. Gaboury, P.M. Siegel, Y. St-Pierre. (2010) Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am. J. Path. 176(6):3023-3031.

A.A.N. Rose, P.A. MacDonald, Z. Dong, C. Russo, N.R. Bertos, R. Simantov, M. Park and P.M. Siegel (2010). GPNMB/Osteoactivin is an independent prognostic indicator of recurrence and a potential therapeutic target in breast cancer. Clin. Cancer Res. 16(7): 2147-2156.

P.M. Siegel and W.J. Muller (2010). Transcription Factor Regulatory Networks in Mammary Epithelial Development and Tumorigenesis. Oncogene. 29(19):2753-2759.

A.A. Rose and P.M. Siegel (2010). Emerging Therapeutic Targets in Breast Cancer Bone Metastasis. Future Oncology 6(1):55-74.


K. Tiedemann, O. Hussein, G. Sadvakassova, Y. Guo, P.M. Siegel, and S.V. Komarova. (2009). Breast cancer derived factors stimulate osteoclastogenesis through synergy between the Ca2+/PKC and TGFbeta/MAPK signaling pathways. J. Biol. Chem. 284(48):33662-33670.

Kristin Roovers, Simona Wagner, Christopher J. Storbeck, Paul O’Reilly, Jason Northey, Juliann Chmielecki, William J. Muller, Peter M. Siegel and Luc A. Sabourin (2009). The Ste20-like kinase SLK is required for ErbB2-driven motility of mammary epithelial cells. Oncogene 28(31):2839-2848.

Dydensborg, AB, Rose, AAN, Grote, D, Paquet, M, Siegel, PM and Bouchard, M. (2009). GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis independently of its effects on cell differentiation. Oncogene 28(29): 2634-2642.

A.A. Mourskaia, Z. Dong, S. Ng, M. Banville, J. Zwaagstra, M. O'Connor-McCourt, P.M. Siegel. (2009). Transforming growth factor-β1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene. 28:1005-15.


J.J. Northey, J. Chmielecki, E. Ngan, C. Russo, M.G. Annis, W. J. Muller, P.M. Siegel. (2008). Signaling through ShcA is required for TGF-beta and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol. Cell Biol. 28(10):3162-76.

A.A.N. Rose, F. Pepin, C. Russo, J.E. Abou Khalil, M. Hallet, P.M. Siegel. (2007). Osteoactivin Promotes Breast Cancer Metastasis to Bone. Mol. Cancer Res. 5(10):1001-14.

A.A. Mourskaia, J.J.Northey, P.M. Siegel. (2007). Targeting aberrant TGF-β signaling in pre-clinical models of cancer. Anticancer Agents Med.Chem. 7(5):504-514

A.A.N. Rose and P.M. Siegel. (2006). Breast Cancer-Derived Factors Facilitate Osteolytic Bone Metastasis. Bull. Cancer. 93(9): 931-943

G.P. Gupta, A.J. Minn, Y. Kang, P.M. Siegel, I. Serganova, C. Cordon-Cardo, A.B. Olshen, W.L. Gerald and J. Massague (2005). Identifying Site-specific Metastasis Genes and Functions. Cold Spring Harb Symp Quant Biol. 70:1-10.

A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos , W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald and J. Massagué. (2005). Genes that mediate breast cancer metastasis to lung. Nature. 436: 518-524.

P.M. Siegel and J. Massagué. (2003). Cytostatic and apoptotic actions of TGF-b in homeostasis and cancer. Nat. Rev. Cancer. 3: 807-820.

P.M. Siegel, W. Shu and J. Massagué. (2003). Mad Upregulation and Id2 Repression Accompany TGF-b Mediated Epithelial Cell Growth Suppression. J. Biol. Chem. 278: 35444-35450.

P.M. Siegel, W. Shu, R.D. Cardiff, W.J. Muller and J. Massagué. (2003). Transforming Growth Factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA. 100: 8430-8435.

Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cardon-Cardo, T.A. Guise and J. Massagué. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3: 537-549.

C-R. Chen, Y. Kang, P.M. Siegel and J. Massagué. (2002). E2F4/5 and p107 as Smad Cofactors linking the TGFb Receptor to c-myc repression. Cell 110: 19-32.


Click for complete Peter Siegel Ph.D. PUBMED